These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11297233)

  • 1. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
    Panasci L; Paiement JP; Christodoulopoulos G; Belenkov A; Malapetsa A; Aloyz R
    Clin Cancer Res; 2001 Mar; 7(3):454-61. PubMed ID: 11297233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
    Christodoulopoulos G; Malapetsa A; Schipper H; Golub E; Radding C; Panasci LC
    Clin Cancer Res; 1999 Aug; 5(8):2178-84. PubMed ID: 10473103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q; Bianchi P; Bezwoda WR
    Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
    Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
    Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance.
    Bramson J; McQuillan A; Aubin R; Alaoui-Jamali M; Batist G; Christodoulopoulos G; Panasci LC
    Mutat Res; 1995 May; 336(3):269-78. PubMed ID: 7739615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia.
    Müller MR; Buschfort C; Thomale J; Lensing C; Rajewsky MF; Seeber S
    Clin Cancer Res; 1997 Nov; 3(11):2055-61. PubMed ID: 9815597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
    Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards.
    Muller C; Christodoulopoulos G; Salles B; Panasci L
    Blood; 1998 Oct; 92(7):2213-9. PubMed ID: 9746757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
    Begleiter A; Mowat M; Israels LG; Johnston JB
    Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
    Sturm I; Bosanquet AG; Hermann S; Güner D; Dörken B; Daniel PT
    Cell Death Differ; 2003 Apr; 10(4):477-84. PubMed ID: 12719725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance mechanisms in chronic lymphocytic leukemia.
    Ribrag V; Massade L; Faussat AM; Dreyfus F; Bayle C; Gouyette A; Marie JP
    Leukemia; 1996 Dec; 10(12):1944-9. PubMed ID: 8946935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione S-transferase activity, sulfhydryl group and glutathione levels, and DNA cross-linking activity with chlorambucil in chronic lymphocytic leukemia.
    Johnston JB; Israels LG; Goldenberg GJ; Anhalt CD; Verburg L; Mowat MR; Begleiter A
    J Natl Cancer Inst; 1990 May; 82(9):776-9. PubMed ID: 2325147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5'-GNC preference for mustard cross-linking is preserved in a restriction fragment.
    Millard JT; Luedtke NW; Spencer RJ
    Anticancer Drug Des; 1996 Sep; 11(6):485-92. PubMed ID: 8836112
    [No Abstract]   [Full Text] [Related]  

  • 14. Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.
    Amrein L; Davidson D; Shawi M; Petruccelli LA; Miller WH; Aloyz R; Panasci L
    Leuk Res; 2011 Aug; 35(8):1080-6. PubMed ID: 21281966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of GSTA2 protects against cell cycle arrest and apoptosis induced by the DNA inter-strand crosslinking nitrogen mustard, mechlorethamine.
    Xie J; Shults K; Flye L; Jiang F; Head DR; Briggs RC
    J Cell Biochem; 2005 May; 95(2):339-51. PubMed ID: 15778998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets in the nitrogen mustard sensitivity of B-cell chronic lymphocyte leukemia (B-CLL).
    Kannan S
    Med Hypotheses; 2006; 67(4):998. PubMed ID: 16757124
    [No Abstract]   [Full Text] [Related]  

  • 17. Apoptosis induced by Magnolia Grandiflora extract in chlorambucil-resistant B-chronic lymphocytic leukemia cells.
    Marin GH; Mansilla E
    J Cancer Res Ther; 2010; 6(4):463-5. PubMed ID: 21358081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells.
    Fonseca SB; Pereira MP; Mourtada R; Gronda M; Horton KL; Hurren R; Minden MD; Schimmer AD; Kelley SO
    Chem Biol; 2011 Apr; 18(4):445-53. PubMed ID: 21513881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
    Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
    Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.